Chasing Numbers: Battling Low Blood Sugar Levels

Chasing Numbers: Battling Low Blood Sugar Levels

Busy Physician Assistant and single mother of three children, Sherifa, is all too familiar with hypoglycemia (low blood sugar).

“There were nights I was afraid to fall asleep,” she recalls. “I stopped getting early low warning symptoms, and there were mornings I would crash and not even know it. It was very scary.”

Low blood sugar can cause confusion, disorientation, loss of consciousness, or worse. This is one of many lows Sherifa recalls having in the past 25 years after being diagnosed with type 1 diabetes. In the last three years, hypoglycemic unawareness has become her biggest challenge, with no warning before her blood sugar dangerously plummets to 40, 30, and even 20 mg/dL.

Sherifa started on the MiniMed 630G system late last year, and it’s had a major impact on her diabetes management. “I haven’t experienced a low since starting on the new system,” she says. “I tried another sensor for a while, but I like the integrated system because it takes action to prevent lows, which is very important to me.”

The MiniMed 630G system uses advanced SmartGuard technology designed to pause insulin delivery if the user does not respond to sensor glucose levels going below a preset limit. SmartGuard technology is the only feature available in the U.S. that takes action against lows*.

“I finally resorted to sleeping near my kids’ bedroom in case I needed help during the night. But now, for first time in years, I’m able to sleep comfortably without concern,” says Sherifa. “It’s been a very taxing journey, but I finally feel at peace.”

Sherifa is part of the MiniMed 670G system Priority Access program, and is eagerly awaiting to transition to the new system when it becomes available starting in the spring. “I am really excited about the MiniMed 670G system because I believe the switch would result in even tighter control of my blood sugar levels, says Sherifa. “I feel like I’m always chasing numbers (high/low glucose levels). Living with diabetes for almost 25 years, the difficult complications associated with this disease are always at the forefront of my mind. Enhanced control means avoiding severe lows and rebound highs, which will positively affect my A1c. In short, I believe the system will enable me to live a more worry-free life with my loved ones!!”

References:

[1] Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold based insulin pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369(3):224–232.

*Measured as low sensor glucose events ≤65 mg/dL.

**Based upon limited sample size and duration of ASPIRE In Home study.

IMPORTANT SAFETY INFORMATION

MiniMed 630G System

The MiniMed 630G system with SmartGuard™ is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of diabetes mellitus in persons, sixteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 630G system includes SmartGuard, which can be programmed to temporarily suspend delivery of insulin for up to two hours when the sensor glucose value falls below a predefined threshold value.

The MiniMed 630G system is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the MiniMed 630G system.

The MiniMed 630G system is not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the SmartGuard suspend on low alarm to take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider.

Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms.

WARNING: Do not use the suspend on low feature to prevent or treat low glucose. The suspend on low feature is designed to suspend insulin delivery when you are unable to respond to the suspend on low alarm. Always confirm your sensor glucose reading using your BG meter, and follow the instructions of your healthcare professional. Using suspend on low to prevent or treat low glucose may result in prolonged hypoglycemia.

Please visit www.medtronicdiabetes.com/importantsafetyinformation for more details.

 MiniMed 670G System

The Medtronic MiniMed 670G system requires a prescription and is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G System includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values.

The Guardian Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).

WARNING: Medtronic performed an evaluation of the MiniMed 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

WARNING: Do not use the Suspend on low feature to prevent or treat low glucose. Always confirm your sensor glucose reading using your BG meter, and follow the instructions of your healthcare professional to treat low glucose. Using Suspend on low alone to prevent or treat low glucose may result in prolonged hypoglycemia.

WARNING: Do not use Auto Mode for a period of time after giving a manual injection of insulin by syringe or pen. Manual injections are not accounted for in Auto Mode. Therefore, Auto Mode could deliver too much insulin. Too much insulin may cause hypoglycemia. Consult with your healthcare professional for how long you need to wait after a manual injection of insulin before you resume Auto Mode.

Contraindications

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Do not use the serter on products other than the Enlite sensor or Guardian Sensor (3). Medtronic cannot guarantee the safety or efficacy of this product if used with other products. The reservoir is contraindicated for the infusion of blood or blood products. Infusion sets are indicated for subcutaneous use only and not for intravenous (IV) infusion or the infusion of blood or blood products. Insulin pump therapy is not recommended for those who are unwilling to perform at least four blood glucose tests per day. As insulin pumps use rapid acting insulin only, BG testing is required to help identify rapid glycemic deterioration due to insulin infusion occlusion, infusion site problems, insulin stability issues, user error, or a combination of these. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional.

General Warnings

The safety of the 670G system has not been studied in people with impaired kidney function. Please let your healthcare professional know if you have kidney disease so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks. The safety of the 670G system has not been studied in pregnant women, people with type 2 diabetes, or in people using other anti-hyperglycemic therapies apart from insulin. Please let your healthcare professional know if any of these conditions apply to you so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks.

For complete safety information, please consult the appropriate User Guide.

Print This Post Print This Post
Tags: , , ,

Post A Comment

Your email address will not be published. Required fields are marked *